These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22031860)

  • 41. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
    Sarkar R; Gao GP; Chirmule N; Tazelaar J; Kazazian HH
    Hum Gene Ther; 2000 Apr; 11(6):881-94. PubMed ID: 10779165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers.
    Garagiola I; Mortarino M; Siboni SM; Boscarino M; Mancuso ME; Biganzoli M; Santagostino E; Peyvandi F
    Eur J Hum Genet; 2021 Feb; 29(2):241-249. PubMed ID: 33082527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in hemophilia A mice.
    Park F
    Hum Gene Ther; 2003 Oct; 14(15):1489-94. PubMed ID: 14577928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene therapy strategies for hemophilia: benefits versus risks.
    Petrus I; Chuah M; VandenDriessche T
    J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene-based continuous expression of FVIIa for the treatment of hemophilia.
    Margaritis P
    Front Biosci (Schol Ed); 2012 Jan; 4(1):287-99. PubMed ID: 22202061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments.
    Bowyer AE; Gosselin RC
    Semin Thromb Hemost; 2023 Sep; 49(6):609-620. PubMed ID: 36473488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
    Moayeri M; Hawley TS; Hawley RG
    Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generation of hyperfunctional recombinant human factor IX variants expressed in human cell line SK-Hep-1.
    Sousa Bomfim A; Corrêa de Freitas MC; Picanço Castro V; Abreu Soares Neto M; Pádua R; Covas DT; Sousa Russo EM
    Biotechnol Lett; 2021 Jan; 43(1):143-152. PubMed ID: 33130980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
    Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
    Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
    Björkman S; Berntorp E
    Clin Pharmacokinet; 2001; 40(11):815-32. PubMed ID: 11735604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
    Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
    Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of hemophilia patients with inhibitors.
    Hedner U; Glazer S
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene Therapy in Hemophilia: Recent Advances.
    Rodríguez-Merchán EC; De Pablo-Moreno JA; Liras A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of factor VII ameliorates bleeding diathesis of factor VIII-deficient mice with inhibitors.
    Yasumoto A; Madoiwa S; Kashiwakura Y; Ishiwata A; Ohmori T; Mizukami H; Ozawa K; Sakata Y; Mimuro J
    Thromb Res; 2013 May; 131(5):444-9. PubMed ID: 23566532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
    Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
    Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.
    Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE
    Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
    Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
    Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A high efficient FVIII variant corrects bleeding in hemophilia A mouse model.
    Mashausi DS; Roy D; Mangukiya HB; Merugu SB; Raza G; Yunus FU; Liu GS; Negi H; Li D
    Biochem Biophys Res Commun; 2022 Dec; 637():358-364. PubMed ID: 35595575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy.
    Brooks AR; Sim D; Gritzan U; Patel C; Blasko E; Feldman RI; Tang L; Ho E; Zhao XY; Apeler H; Murphy JE
    J Thromb Haemost; 2013 Sep; 11(9):1699-706. PubMed ID: 23692404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.